Arena Pharmaceuticals (ARNA -3.6%) says an FDA advisory committee will meet in the second quarter to discuss the company's resubmitted application for its weight-loss drug lorcaserin. There are concerns by many analysts that lorcaserin may not be as effective as other drugs being developed.